Company Overview of Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc., a preclinical-stage biopharmaceutical company, intends to develop medicines for use in treating human viral diseases. The company focuses on developing inhibitors that viral replication enzymes and viral replication protein. It is developing antiviral therapeutics for human diseases, including Hepatitis C virus, Influenza virus, and Norovirus. The company also develops targeted in-house chemical libraries consisting of antiviral compounds of nucleosides, non-nucleoside inhibitors, metal-binding inhibitors, and fragments. In addition, it is developing compounds that inhibit HCV helicase, an enzyme that is essential for hepatitis C viral replication. The company was fou...
19805 North Creek Parkway
Bothell, WA 98011
Founded in 2007
Key Executives for Cocrystal Pharma, Inc.
Co-Founder and President
Total Annual Compensation: $180.0K
Co-Founder, Vice Chairman, Senior Advisor and Member of Scientific Review Committee
Total Annual Compensation: $250.0K
Chief Financial Officer , Principal Accounting Officer and Treasurer
Total Annual Compensation: $150.0K
Compensation as of Fiscal Year 2014.
Cocrystal Pharma, Inc. Key Developments
Cocrystal Pharma, Inc Appoints Douglas Mayers as Chief Medical Officer
Sep 24 15
Cocrystal Pharma, Inc. announced the appointment of Douglas Mayers, M.D., to the position of chief medical officer (CMO).
Dr. Mayers is a specialist in infectious diseases and has nearly 27 years of medical and clinical development experience spanning all phases of global clinical research & development and commercialization. Most recently, Dr. Mayers spent the past year at the United States Army Medical Research Institute of Infectious Diseases working with colleagues to discover and develop drugs against the Ebola virus.
Cocrystal Pharma, Inc. Appoints Jeffrey Meckler as Chief Executive Officer, Effective from October 1, 2015
Sep 21 15
Cocrystal Pharma, Inc. announced that its Board of Directors has appointed board member Jeffrey Meckler to the position of Chief Executive Officer (CEO), effective October 1, 2015. Mr. Meckler had been serving as company's Interim CEO since March 31, 2015. Mr. Meckler has over 25 years of experience in life science companies, including 17 years at Pfizer Inc. in a variety of positions, including Manufacturing, Systems, Market Research and Corporate Finance. Mr. Meckler currently serves as the Chairman of the Board for Retrophin, Inc. Mr. Meckler has also served as Managing Director of The Andra Group.
Cocrystal Pharma, Inc. Names Walt Addison Linscott, Esq. as General Counsel and Corporate Secretary
Jul 15 15
Cocrystal Pharma, Inc. announced the appointment of Walt Addison Linscott, Esq. as General Counsel and Corporate Secretary. Most recently, Linscott served as Global Strategic Legal Advisor for Thompson Hine, LLP. Linscott's experience as a lawyer spans 25 years and includes serving as General Counsel and Corporate Secretary of Carestream Health, Inc., leading as Chair of the Life Sciences practice and office managing partner of an international law firm and serving as the Vice President, General Counsel and Corporate Secretary of a branded pharmaceutical company that was sold to Abbott Laboratories.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 17, 2015
November 25, 2014
|RFS Pharma, LLC